Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
Status:
Terminated
Trial end date:
2018-05-10
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study with Cohort Expansion of Pentostatin, Bendamustine and Ofatumumab
(PBO) for patients with previously treated Chronic Lymphocytic Leukemia (CLL) and B-cell
Non-Hodgkin's Lymphoma (B- cell NHL). The purpose of this study is to determine the optimal
dose of bendamustine in combination with pentostatin and ofatumumab, and then to see how safe
these three drugs work together.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University